Adverse Reactions Sample Clauses

Adverse Reactions. Nmap Technology is not designed to crash systems and should not pose any problems for standards-conformant network equipment. However, some systems, devices, and applications have occasionally been reported to react adversely to port scans, OS detection, service detection probes, and NSE scripts. This is an error in the network device in question, and not in Nmap Technology. Nmap Technology should not be used against mission-critical systems without careful monitoring.

Adverse Reactions. The Company and the Manufacturer shall observe the procedures and notification requirements with respect to Adverse Reactions described in Schedule 7.5 attached hereto.

Adverse Reactions. Roche shall be responsible for reporting to the appropriate regulatory authorities all adverse events related to the use of Product worldwide, except that prior to the time Gilead transfers ownership of the IND to Roche as provided in Section 3.2(b), Gilead shall be responsible for the reporting of such adverse events in the U.S. Adverse events related to the use of Product worldwide shall be recorded in a single database, and the parties will coordinate their efforts to assure that all adverse events are reported properly.

Adverse Reactions. Abrupt reversal of opioid effects in persons who are physically dependent on opioids may precipitate an acute opioid withdrawal syndrome. The acute opioid withdrawal syndrome may include: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, tachycardia. A patient who develops a suspected adverse reaction to naloxone should call the pharmacy to report it. Pharmacists can recommend symptom management of the reaction, and/or patient referral. Development of life‐threatening symptoms should be immediately referred to the closest emergency room or urgent care clinic. Pharmacists should then report the adverse reaction to the FDA at MedWatch, found online at xxxxx://xxx.xxxxxxxxxx.xxx.xxx/scripts/medwatch/medwatch‐online.htm or 1‐800‐FDA‐

Adverse Reactions. Each party shall be responsible for maintaining such records and making such reports as may be required in connection with any regulatory approval held by the party. Each party shall immediately inform the other of all adverse drug experience reports and other information relating to the safety or effectiveness of Product which come to its attention.

Adverse Reactions. THERAPEUTICS shall be responsible for reporting to the appropriate regulatory authorities any and all adverse events related to the use of any Category I and Category II SDC Product(s), while INNOVATIVE shall bear said responsibility for all Category III SDC Product(s). Adverse events related to the use of any SDC Product(s) shall be recorded in a single database, maintained by THERAPEUTICS and the Parties will coordinate their efforts to assure that all adverse events are properly reported INNOVATIVE will report all adverse events to THERAPEUTICS within 5 days of notification regardless of the Category of the Product. In the event of termination or breach, or for any other reason THERAPEUTICS transfers its ownership of any Regulatory Filings for any SDC Product(s) to INNOVATIVE, INNOVATIVE shall assume and become responsible for the reporting of adverse events for any Category I and Category II SDC Product(s).

Adverse Reactions. The CLIENT agrees that only CLIENT it, neither Investigator nor the SMO, is responsible for the costs of diagnosis, care and treatment of any undesirable side effects, adverse reactions, illness or injury to a participant (trial subject) in the Clinical Trial which in the reasonable judgment of the Principal Investigator are determined to result from participation in the Clinical Trial, except for such costs that arise directly from (i) the negligent activities, reckless misconduct or intentional misconduct of the Principal Investigator or his/her staff or (ii) their failure to adhere to the terms of the Protocol. This section is not intended to create any third-party contractual benefit for any participants in the Clinical Trial. The Investigator undertakes to document all Serious Adverse Events on the CRF. Any Serious Adverse Event which is serious as defined herein below shall be reported immediately (within 24 hours of its knowledge) by telephone or fax to the CLIENT clinical research associate or clinical research physician and followed up with a written report. An event is considered as a Serious Adverse Event if it fulfills at least one of the following criteria: • Results in death • Life threatening • Results in persistent or significant disability/incapacity • Requires or prolongs in-patient hospitalization • Results in congenital anomaly • Any other medically significant event

Adverse Reactions. Distributor shall advise Keystone within twenty-four (24) hours of any adverse reaction, injury or death resulting from any use of the Products (an “Adverse Reaction”) of which it becomes aware. Distributor shall also, within five (5) days thereafter, provide Keystone with a written report stating the full facts known to it concerning the Adverse Reaction, including, but not limited to, customer name, address, telephone number and Product lot or serial number. Keystone shall, from time to time, provide Distributor with written procedures regarding the information required by Keystone in the event of any Adverse Reaction. At all times during the term of this Agreement, Distributor shall have appropriate written procedures established for processing any Adverse Reaction, and shall provide the same to Keystone upon request. As part of such procedures, Distributor shall establish a means for properly (a) tracking delivery of Products to customers (including all customers who receive Products from subdistributors), including, without limitation, tracking which customers have received Products from particular lot numbers and/or bearing particular serial numbers, and (b) maintaining its distribution records for the Products for a reasonable time period. All information related to any Adverse Reaction shall be considered Confidential Information of Keystone, and shall therefore be subject to the provisions of Section 7 below.

Adverse Reactions. Sponsor agrees that HCRI is not responsible for the costs of diagnosis, care and treatment of any undesirable side effects, adverse reactions, illness or injury to a participant in the Trial which result from participation in the Trial, except to the extent such costs arise directly from HCRI’s gross negligence or reckless or intentional misconduct. This section is not intended to create any third-party contractual benefit for any participants or Clinical Sites in the Trial.

Adverse Reactions. 43 SECTION 11.3